Haemophilia B (or hemophilia B) is a blood clotting disorder caused by a mutation of the factor IX gene, leading to a deficiency of factor IX. It is the second-most common form of haemophilia, rarer than haemophilia A. Haemophilia B was first recognized as a different kind of haemophilia in 1952. It is sometimes called Christmas disease, named after Stephen Christmas, the first patient described with this disease. In addition, the first report of its identification was published in the Christmas edition of the British Medical Journal. The presentation of hemophilia B is consistent with easy bruising, urinary tract bleed and nosebleeds. Additionally, the affected individual may experience bleeding into their joints. The factor IX gene is located on the X chromosome (Xq27.1-q27.2). It is an X-linked recessive trait, which explains why, as in haemophilia A, usually only males are affected. In 1990, George Brownlee and Merlin Crossley showed that two sets of genetic mutations were preventing two key ...
... is a bleeding disorder that slows the blood clotting process. People with this disorder experience prolonged bleeding or oozing following an injury or surgery. In severe cases of hemophilia, heavy bleeding occurs after minor trauma or even in the absence of injury. Serious complications can result from bleeding into the joints, muscles, brain, or other internal organs. Milder forms may not become apparent until abnormal bleeding occurs following surgery or a serious injury. People with an unusual form of hemophilia B, known as hemophilia B Leyden, experience episodes of excessive bleeding in childhood but have few bleeding problems after puberty. Hemophilia B is inherited in an X-linked recessive pattern and is caused by mutations in the F9 gene ...
... is a bleeding disorder that slows the blood clotting process. People with this disorder experience prolonged bleeding or oozing following an injury or surgery. In severe cases of hemophilia, heavy bleeding occurs after minor trauma or even in the absence of injury. Serious complications can result from bleeding into the joints, muscles, brain, or other internal organs. Milder forms may not become apparent until abnormal bleeding occurs following surgery or a serious injury. People with an unusual form of hemophilia B, known as hemophilia B Leyden, experience episodes of excessive bleeding in childhood but have few bleeding problems after puberty. Hemophilia B is inherited in an X-linked recessive pattern and is caused by mutations in the F9 gene ...
CHAPTER 123 HEMOPHILIA A AND HEMOPHILIA B Williams Hematology CHAPTER 123 HEMOPHILIA A AND HEMOPHILIA B HAROLD R. ROBERTS MAUREANE HOFFMAN Hemophilia A (Classic Hemophilia, Factor Viii Deficiency) Definition and History Etiology and Pathogenesis Genetics Prenatal Diagnosis and Carrier Detection Clinical Features Laboratory Features Differential Diagnosis Therapy Course and Prognosis Hemophilia B (Factor IX Deficiency,…
TY - JOUR. T1 - Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. AU - Powell, Jerry S. AU - Pasi, K. John. AU - Ragni, Margaret V.. AU - Ozelo, Margareth C.. AU - Valentino, Leonard A.. AU - Mahlangu, Johnny N.. AU - Josephson, Neil C.. AU - Perry, David. AU - Manco-Johnson, Marilyn J.. AU - Apte, Shashikant. AU - Baker, Ross I.. AU - Chan, Godfrey C.. AU - Novitzky, Nicolas. AU - Wong, Raymond S.. AU - Krassova, Snejana. AU - Allen, Geoffrey. AU - Jiang, Haiyan. AU - Innes, Alison. AU - Li, Shuanglian. AU - Cristiano, Lynda M.. AU - Goyal, Jaya. AU - Sommer, Jurg M.. AU - Dumont, Jennifer A.. AU - Nugent, Karen. AU - Vigliani, Gloria. AU - Brennan, Aoife. AU - Luk, Alvin. AU - Pierce, Glenn F.. PY - 2013. Y1 - 2013. N2 - BACKGROUND: Prophylactic factor replacement in patients with hemophilia B improves outcomes but requires frequent injections. A recombinant factor IX Fc fusion protein (rFIXFc) with a prolonged half-life was developed to reduce the frequency of ...
Investigators report no evidence of toxicity in the four hemophilia B patients enrolled to date in a gene therapy trial using a vector under development at St. Jude Childrens Research Hospital and UCL (University College London) to correct the inherited bleeding disorder.. This trial was designed primarily as a safety test, with low and intermediate doses of the vector expected to produce little detectable Factor IX. The Factor IX protein helps the blood form clots. Individual with hemophilia B lack adequate levels of this clotting factor. The first participant in the open-label Phase I/II trial had an unexpectedly high level of Factor IX expression after receiving the lowest dose of the vector being tested in this study. Levels of the Factor IX protein rose from less than 1 percent to 2 percent of normal after the experimental vector was infused into the patient.. The patients Factor IX production remains elevated more than nine months later. Since the infusion the patient has also not ...
Valder Arruda, M.D., Ph.D.. Our laboratory is interested in the development of gene-based strategies for the treatment of bleeding and thrombotic diseases. In a collaborative effort, we, along with others, have carried out early-phase clinical studies on adeno-associated viral (AAV) vectors for the treatment of severe hemophilia B (factor IX deficiency). Current projects are focused on translational research studies on the efficacy and safety of intravascular delivery of AAV vectors to skeletal muscle or liver of dogs and mice with severe hemophilia B and hemophilia A (factor VIII deficiency). We are developing novel variants of coagulation factor VIII or factor IX with enhanced biological activity to optimize gene and protein based strategies. We have identified a factor IX variant (FIX Padua) with 8-10-fold higher specific activity, and this molecule is now used for gene therapy in hemophilia B dog models.. Recently the focus of the laboratory has been on the use of gene therapy to treat a ...
TY - JOUR. T1 - Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. AU - Escobar, M. A.. AU - Tehranchi, R.. AU - Karim, F. A.. AU - Caliskan, U.. AU - Chowdary, P.. AU - Colberg, T.. AU - Giangrande, P.. AU - Giermasz, Adam. AU - Mancuso, M. E.. AU - Serban, M.. AU - Tsay, W.. AU - Mahlangu, J. N.. PY - 2017/1/1. Y1 - 2017/1/1. N2 - Introduction: Surgery in patients with haemophilia B carries a high risk of excessive bleeding and requires adequate haemostatic control until wound healing. Nonacog beta pegol, a long-acting recombinant glycoPEGylated factor IX (FIX), was used in the perioperative management of patients undergoing major surgery. Aim: To evaluate the efficacy and safety of nonacog beta pegol in patients with haemophilia B who undergo major surgery. Methods: This was an open-label, multicentre, non-controlled surgery trial aimed at assessing peri- and postoperative efficacy and safety of nonacog beta pegol in 13 previously ...
Hemophilia B is a genetic X-linked bleeding disorder caused by a deficiency in blood-clotting Factor IX (FIX) activity. FIX is synthesized in the liver and circulates in the blood as a proenzyme. Current treatment for hemophilia B is based on replacement of the deficient FIX with IV injections of recombinant FIX protein prophylactically or as needed to treat bleeding episodes. This clinical program will test a gene transfer approach involving the use of a gene delivery vector carrying a FIX gene. This first-in-humans study is intended to evaluate the safety, kinetics, and if possible, the dose of AskBio009 required to achieve stable plasma FIX activity between 10% and 40% of normal activity ...
Hemophilia B is a genetic X-linked bleeding disorder caused by a deficiency in blood-clotting Factor IX (FIX) activity. FIX is synthesized in the liver and circulates in the blood as a proenzyme. Current treatment for hemophilia B is based on replacement of the deficient FIX with IV injections of recombinant FIX protein prophylactically or as needed to treat bleeding episodes. This clinical program will test a gene transfer approach involving the use of a gene delivery vector carrying a FIX gene. This first-in-humans study is intended to evaluate the safety, kinetics, and if possible, the dose of AskBio009 required to achieve stable plasma FIX activity between 10% and 40% of normal activity ...
Control and Prevention of Bleeding Episodes in Hemophilia B. BeneFIX®, Coagulation Factor IX (Recombinant), is indicated for the control and prevention of bleeding episodes in adult and pediatric patients with hemophilia B (congenital factor IX deficiency or Christmas disease).. Peri-operative Management in Patients with Hemophilia B. BeneFIX®, Coagulation Factor IX (Recombinant), is indicated for peri-operative management in adult and pediatric patients with hemophilia B.. BeneFIX®, Coagulation Factor IX (Recombinant), is NOT indicated for:. a. treatment of other factor deficiencies (e.g., factors II, VII, VIII, and X),. b. treatment of hemophilia A patients with inhibitors to factor VIII,. c. reversal of coumarin-induced anticoagulation,. d. treatment of bleeding due to low levels of liver-dependent coagulation factors.. For indications, dosing and other information, please refer to the prescribing information.. ...
Hemophilia is a rare genetic bleeding disorder that causes the blood to take a long time to clot as a result of a deficiency in one of several blood clotting factors, and occurs almost exclusively in males. People with hemophilia face specific risks as they are not able to form blood clots efficiently and are at risk for excessive and recurrent bleeding from modest injuries, which have the potential to be life threatening. People with severe hemophilia often bleed spontaneously into their muscles or joints. The incidence of hemophilia B is one in 25,000 male births. People with hemophilia B have a deficiency in clotting factor IX, a specific protein in the blood. Hemophilia B is also called congenital factor IX deficiency or Christmas disease. Current standard of care requires recurrent intravenous infusions of either plasma-derived or recombinant factor IX to control and prevent bleeding episodes. There exists a significant need for novel therapeutics to treat people living with ...
Introduction Despite the advent of extended half-life factor IX (FIX) products with the potential for 14 days or longer prophylactic dosing in patients with severe hemophilia B, long-term data on the use of ≥14-day dosing are lacking for prolonged periods of observation. A post hoc analysis of the B-LONG Phase 3 trial showed that ~50% of subjects in the individualized interval prophylaxis treatment arm (Arm 2, n=29) used extended dosing intervals (≥14 days) and had low annualized bleed rates (ABRs) that were similar to ABRs in subjects on other dosing intervals in Arm 2.1. The purpose of this analysis was to evaluate whether sustained ≥14-day dosing with recombinant FIX Fc fusion protein (rFIXFc) can provide safe and effective protection from bleeding in selected patients with severe hemophilia B over time in a near real-world setting. Methods B-LONG (NCT01027364) enrolled 123 adults and adolescents ≥12 years of age into 1 of 4 treatment arms: weekly prophylaxis (50 IU/kg every 7 days, ...
article{6540f780-e849-4367-a13e-127a460cab4a, abstract = {Haemophilia B, an X-linked recessive bleeding disorder characterized by lack or deficiency of factor IX, has been shown to be caused by any of a variety of DNA abnormalities (partial or total deletions, nonsense or missense mutations). Since in most countries carrier detection is based on factor IX coagulant activity (FIX:C) assay, this study was designed to determine whether carriers FIX:C values are dependent on the severity of haemophilia (mild, moderate or severe) or on the genetic anomaly in the family. FIX:C concentrations were studied in 28 obligate carriers, 39 women known to carry the mutation and 33 verified noncarriers subgrouped by severity of disorder or genetic anomaly. No significant subgroup differences in FIX:C values were found, thus suggesting the level of FIX:C concentrations in carriers to be unaffected by the severity of haemophilia, or by its expression (i.e. deficient or dysfunctional factor IX). The specificity ...
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to the investigational gene therapy, AMT-060 (uniQure), for the treatment of severe hemophilia B.
Home Health Care, which includes physical, occupational and speech therapies, as well as nursing, encompasses a broad spectrum of health and social services for recovering, disabled or chronically ill persons... ...
Neurology news, research and treatment studies for epilepsy, neurodegenerative disorders, patients with MS and other brain and central nervous system disorders and diseases.
Psychiatry healthcare professionals gain a thorough knowledge base of psychiatric disorder information to offer the best patient care. Get our FREE app now.
Background: Data from earlier hemophilia B (HB) AAV-mediated liver gene transfer trials demonstrated a dose-dependent, capsid-specific immune response that may result in clearance of transduced hepatocytes and loss of transgene expression (Manno et al. 2006, Mingozzi et al. 2007). This has not posed major safety concerns, but may limit efficacy. Prior work incorporated the use of steroids to abort this immune response and maintain factor IX (FIX) expression (Nathwani et al 2014). The percent of transgene expression lost increased with number of elapsed days from transaminase elevation to steroid initiation. Once vector responsiveness to steroids is established, the need for steroids is not a limitation in and of itself but highlights the requirement to reliably and expeditiously recognize an immune response and initiate steroids. Here we present our immunomonitoring data following infusion of SPK-9001, an AAV vector designed to achieve therapeutic FIX:C at a low vector dose to minimize ...
In an article release by the CDC (Center for Disease Control and Prevention), research reports key findings related to the formation of inhibitors (antibodies) in patients who have hemophilia. The study shows that hemophilia A and hemophilia B patients who develop inhibitors are likely to have a specific type of antibody called immunoglobulin G subclass 4, or IgG4. In the event that traditional inhibitor tests do not provide clear results, testing for these antibodies instead may help clarify whether an inhibitor is present.. Inhibitors are antibodies (protein) that prevents or stops infused factor from working. For those with bleeding disorders like hemophilia A and hemophilia B, inhibitors often develop because the bodys immune system identifies the clotting factor as foreign. A blood test called Nijmegen-Bethesda Assay (NBA) is used to diagnose inhibitors.. For some cases, NBA can produce an unclear result as to whether a patient has an inhibitor or not. The CDC researchers have addressed ...
Jay Konduros, the former aerospace engineer who has a blood disorder called hemophilia B, use to sprint home many times succeeding disparate times a year after coincidentally cutting and colliding himself. He would inject himself with refrigerated blood clotting element to avoid interior bleeding and substantial bruising and swelling.. Then he admitted himself in a clinical trial, sustaining an inventive gene therapy at Childrens Hospital of Philadelphia. Almost instantly he commenced producing the missing clotting factor. After a few weeks he relinquished a heavy box on his shin, he observed an injury develop and recoil within hours.. Konduras, 53, who operates a bakery and a cafe in southeastern Ontario, is one of the 10 men receiving in an early-stage trial financed by Spark Therapeutics. On Wednesday researchers announced that an individual intravenous infusion of Sparks novel gene therapy empowered patients to securely produce adequate clotting factor to avoid hazardous bleeding episodes ...
A single treatment with gene therapy, an experimental technique for fixing faulty genes, has been shown to boost output of a vital blood clotting factor, possibly offering a long-term solution for people with hemophilia B.
FDA Approves Biogen Idecs ALPROLIX™, the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart
Experts available for hemophilia B consulting, expert witness, or analyst services for business, legal, and technical professionals.
An open-label, uncontrolled, single-dose, dose-escalation, multi-centre trial investigating the safety and efficacy of systemic administration of AAV5-hFIX, an adeno-associated viral vector containing a codon-optimised human factor IX gene, to severe haemophilia B ...
A Phase III clinical trial led by UC Davis researchers has confirmed that a new coagulation factor (rFIXFc) dramatically reduces the number of injections needed to maintain effective clotting for hemophilia B patients.
Hemophilia A. Hemophilia A is a heredity bleeding disorder that is caused by a lack of clotting factor VIII. As a result, individuals with this condition suffer from bleeding into joints and other complications. For the most part, men have hemophilia A as the defective gene is found on the X chromosome. A woman who has the defective gene is considered a carrier and any male offspring have a 50% chance of having hemophilia A and female offspring a 50% chance of being a carrier. It affects one in 10,000 people. With treatment, individuals are able to lead relatively normal lives.. Hemophilia B. Hemophilia B is a blood clotting disorder caused by a mutation of the Factor IX gene. It is rarer than hemophilia A and affected royal families in both Europe and Russia. It affects one in 25,000 men. Replacement of Factor IX through recombinant therapy allows individuals to lead relatively normal lives.. Von Willebrand Disease. The most common bleeding disorder, Von Willebrand affects about 1.25 million ...
https://www.hemophilia.org/Bleeding-Disorders/Types-of-Bleeding-Disorders/Hemophilia-B Haemophilia B] is a disease caused by a deficiency in the secretion of coagulation factor IX (FIX) which results in the impaired blood coagulation cascade,ref name=ena,Nathwani et al. (2011). Adenovirusassociated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357-2365,/ref,. Thus, the disease is manifested by blood dotting defects. Considering the plasma cells ability to produce de novo protein, it opens up an opportunity for the production of deficient protein and thus the potential cure for protein-deficiency diseases. This review article will focus on the methods used to investigate the ability of activated B cells differentiated from primary naive human B cells to produce functioning factor IX by [https://www.addgene.org/crispr/guide/CRISPR/Cas9 CRISPR/Cas9] genome editing tool and [https://blog.addgene.org/crispr-101-homology-directed-repair homology-directed ...
Merck & Co. Inc. (NYSE:MRK) said that, it is pressing ahead with Phase III trials aimed at mimicking the worlds biggest selling drug as it looks to create future growth with biosimilars.. Merck & Co. Inc. (NYSE:MRK) belongs to Healthcare sector. Its net profit margin is 11.20% and weekly performance is 2.16%. On last trading day company shares ended up at $52.10. Merck & Co. Inc. (NYSE:MRK) distance from 50-day simple moving average (SMA50) is 2.10%. Biogen Inc. (NASDAQ:BIIB) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending that marketing authorisation be granted for Alprolix® (rFIXFc), a recombinant factor IX Fc fusion protein therapy for the treatment of haemophilia B. If approved, Alprolix would be among the first therapies in the European Union (EU) to offer people living with haemophilia B prolonged protection against bleeding episodes with prophylactic dosing intervals.. Biogen Inc. ...
Patient Presentation An 4-year-old male came to clinic in December for his well child care. He was known to have Factor IX deficiency after he had spontaneous bleeding into an elbow as a toddler. He was receiving prophylactic factor treatment at the regional childrens hospital. The past medical history showed no other major bleeding episodes.…
Increases in FIX Activity Sustained at up to 51% of Normal, with Mean FIX of 38% of Normal at Twelve Weeks After Administration None of the Patients Rec...
Patients with a form of thechronic blood disorder hemophilia will soon have a new therapythat not only treats episodes of excessive bleeding, but helpsto prevent them.
Source: CSL Behring & reported by http://www.prnewswire.com/ ORLANDO, Fla., July 26, 2016 /PRNewswire/ -- CSL Behring today announced new data from its Phase
Oherwydd y potensial i imiwnedd sydd eisoes yn bodoli effeithion negyddol ar effeithiolrwydd therapi genynnau syn seiliedig ar firws syn gysylltiedig ag adeno (AAV), mae llawer o dreialon clinigol o therapi genynnau wediu seilio ar AAV yn eithrio cleifion â gwrthgyrff niwtraleiddio syn bodoli eisoes (NABs) a gyfeirir yn erbyn y proteinau capsid. Miesbach et al. (Blood, 2018) wedi adrodd or blaen ar ddiogelwch ac effeithiolrwydd AMT-060 (AAV5-hFIX) mewn 10 o ddynion syn oedolion â hemoffilia B. Cyn triniaeth, roedd pob un or dynion hyn yn benderfynol o fod yn negyddol ar gyfer NABs gwrth-AAV5 gan ddefnyddio a assay gwyrdd-fflwroleuol wedii seilio ar brotein
FDA approves new therapy for hemophilia The Food and Drug Administration has approved the first hemophilia B treatment designed to decrease frequency of injections to prevent the excessive bleeding the clotting disorder causes. The medicine, Alprolix, is for preventing or shortening bleeding episodes in adults and children with hemophilia B, the second-most common type. It affects about 3,300 Americans, mostly males. Manufacturer Biogen Idec Inc. of Cambridge, Mass., calls it the first major advance for
IX.icago doctor helps families elimination Genetic DiseaseIn February 2004, Jennifer and Brian Lester welcomed a healthy baby girl. The Lester not have a problem understanding, but uses a fertility treatment has in vitro fertilization with preimplantation genetic diagnosis as Jennifer s father haemophilia B and Jennifer is a carrier pms . Hemophilia B is an inherited disease that the blood from clotting properly. It is caused by a mutation in a gene, the lack of a plasma protein called factor IX. Women like Jennifer who are carriers of the mutation are always concerned sons. One half of her daughters will be carriers. Used to create used to create embryos affected affected nor carriers are identified - which the affected blood line. By PGD Jennifer daughters never on the disease, to care for their children.. Give Ecstatic with the revolutionary process of PGD and Jennifer Jennifer and Brian a healthy daughter, the Lesters again sought the help of Dr. Randy Morris, a specialist in PGD and ...
Haemophilia B is one of the most important inherited disorders of haemostasis in Rhodesian Ridgeback Dogs. The underlying pathomechanism of haemophilia B is a lack or decreased activity of factor IX that plays a critical role in the coagulation cascade. Affected dogs present with hemorrhage that can vary from mild to severe depending on the degree of the disease. The clinical signs include haematomas of large sizes, bleeding of the nose, skin, muscles and joints. If the disease is severe and no precautions are taken, affected dogs can bleed to death after surgery or injuries. ...
FIXKM : Container/Tube: Preferred: Yellow top (ACD solution B) Acceptable: EDTA or sodium citrate Specimen Volume: 6 mL Collection Instructions: 1. Invert several times to mix blood. 2. Send specimen in original tube.
Out of 5 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 4 rate it "Buy", 1 "Sell", while 0 "Hold". This means 80% are positive. $22 is the highest target while $12 is the lowest. The $17 average target is 86.00% above todays ($9.14) stock price. Sangamo Biosciences was the topic in 7 analyst reports since August 8, 2015 according to StockzIntelligence Inc. Jefferies reinitiated the stock on October 23 with "Buy" rating. JP Morgan maintained it with "Overweight" rating and $22 target price in an August 8 report. Cowen & Co maintained the shares of SGMO in a report on September 4 with "Buy" rating. Finally, Wedbush maintained the stock with "Buy" rating in a September 2 report.. The institutional sentiment decreased to 0.97 in Q2 2015. Its down 0.39, from 1.36 in 2015Q1. The ratio dived, as 32 funds sold all Sangamo Biosciences, Inc. shares owned while 46 reduced positions. 26 funds bought stakes while 50 increased positions. They now own 50.47 million shares or 3.34% less from 52.21 ...
The Materials are provided on an "as is" and "as available basis" and do not purport to be full or complete. The Company and its affiliates believe that the source of the Materials is reliable however they cannot and do not guarantee, either expressly or implicitly, and accept no liability for, the accuracy, validity, timeliness, merchantability or completeness of any information or data (whether prepared by the Company, its affiliates or by any third party) for any particular purpose or use or that the information or data will be free from error. The Company and its affiliates do not undertake any responsibility for any reliance which is placed by any person on any statements or opinions which are expressed herein. Neither the Company, nor any of its affiliates, directors, officers or employees will be liable or have any responsibility of any kind for any loss or damage that any person may incur resulting from the use of this information.Nothing contained in this website constitutes financial, ...
The therapeutic armamentarium for hemophilia is rapidly expanding (18, 19, 31). However, the clinical development of several new products has been marred by unanticipated thrombotic complications and subject deaths (17-19). The only published clinical gene therapy trial in subjects with HB expressing FIX-R338L (n = 10) used a single low vector dose that resulted in most subjects (n = 9) having less than 50% normal FIX activity (mean 35% normal; ref. 10). Elucidating the mechanism of the increased specific activity of FIX-R338L has important safety implications as gene therapy with FIX-R338L advances into pivotal phase III studies with larger study cohorts as well as higher targeted FIX activity levels.. Potential mechanisms of increased specific activity of FIX include enhancements in FIX activation, resistance to AT inactivation (32), FVIIIa-independent activity (33, 34), and improvements in the interaction with FVIIIa (35-37). Herein, we provide mechanistic data that demonstrate FIX/FIXa-R338L ...
HEM B symptoms, causes, diagnosis, and treatment information for HEM B (Hemophilia B) with alternative diagnoses, full-text book chapters, misdiagnosis, research treatments, prevention, and prognosis.
2017. okt ber 2, h tf A Szimul ci s Oktat si K zpont a j vend beli s a m r eg szs g gyi tanulm nyaikkal v gzett szakemberek k pz se mellett kiemelten fontosnak tartja, hogy azok sz m ra is seg ts get ny jtson, akik eg szs g gyi llapotuk miatt valamilyen ter pi ban r szes lnek. Legut bb a s lyos Hemophilia B miatt gondozott ron j rt n lunk, aki heti k t alkalommal profilaktikus intrav n s faktorp tl sban r szes l. A 12 ves nagyfi elindulva az n ll sod s tj n, szeretn tv llalni a sz l kt l az otthoni gondoz s feladat t. A MediSkillsLab-ben ron az intrav n s faktorp tl st K v r Anna doktorn vezet s vel, szakmai protokollok alapj n tanulhatta meg intrav n s gyakorl karon. Int zm ny nk r mmel vesz r szt a k s bbiekben is hasonl egy ttm k d sekben.. ...
Cleanliness is one the biggest draws of living with cats. So, if you start to detect a bad odor from your cat, you need to take notice. In most cases, foul feline smells are a sign that something is seriously wrong. ...